Guesly Delva, MD
Infectious Disease · Spring Hill, FLNPI 1750562724
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $379 of the $531 with a category attached, or 71.4%. 9 manufacturers reported payments, led by Insmed, Inc. at 32.2% of the total. Reporting peaked in 2019 at $347 and has fallen 95.2% since, to $17 in 2025. That places this record below the midpoint for infectious disease clinicians in FL, where the typical reported total is $652.
Across 27 payments — averaging $19.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insmed, Inc.$171
- Abbott$81
- Melinta Therapeutics, LLC$69
- Gilead$65
- Viiv Healthcare Company$63
- Merck$31
- plus $50 from 3 others
What the payments were for
- Food & beverage$37971%
- Education$15229%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Insmed, Inc. | 7 | $171 |
| Abbott | 4 | $81 |
| Melinta Therapeutics, LLC | 4 | $69 |
| Gilead | 3 | $65 |
| Viiv Healthcare Company | 3 | $63 |
| Merck | 2 | $31 |
| Smith+Nephew | 2 | $26 |
| Spinal Simplicity, LLC | 1 | $19 |
| Saluda Medical Americas, Inc. | 1 | $5 |
How this compares
$531 in reported general payments places this provider in the 45th percentile of 669 infectious disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Daptomycin | 95 | $77,158 |
| Vancomycin Hcl | 180 | $35,341 |
| Cefepime Hcl | 130 | $26,526 |
| ErtapenemErtapenem Sodium | 36 | $21,798 |
| Meropenem | 108 | $19,848 |
| CeftriaxoneCeftriaxone Sodium | 96 | $17,540 |
| MicafunginMicafungin Sodium | 22 | $10,255 |
| Ampicillin Sodium | 20 | $4,630 |
| Ampicillin-SulbactamAmpicillin Sod/Sulbactam Sod | 18 | $4,258 |
| Piperacillin-TazobactamPiperacillin Sodium/Tazobactam | 23 | $4,154 |
| Cefazolin Sodium | 40 | $1,660 |
| Cefdinir | 13 | $153 |
| Diphenhydramine Hcl | 20 | $71 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Spring Hill
- Lennox ArchibaldGainesville$2.1M
- Moti RamgopalFort Pierce$1.1M
- Juan DiazAltamonte Springs$980K
- Charlotte-Paige RolleOrlando$619K
- Kenneth AlexanderOrlando$474K
- Douglas BrustMiami$359K
- Christopher CooperAltamonte Springs$278K
- Federico HinestrosaOrlando$276K
- Cynthia RiveraMiami Beach$265K
- Sally AlrabaaTampa$250K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.